# Value Partners Health Care Fund

# A UCITS-Compliant Fund 1

NAV per unit: Class A USD Unhedged - USD10.91

Fund size : USD24.0 million



30 June 2017

- Value Partners Health Care Fund (the "Fund") primarily invests in equities and equity-related securities in healthcare companies in China or companies which derive a significant part of their revenue from the PRC and which are listed on other worldwide stock markets.
- The Fund may have significant investments in the securities of high growth companies and that these securities may be very volatile. The value of the Fund could decrease substantially within a short time. Investors may lose part or all of their investment.
- · The Fund's investments in China are subject to a higher level of market risk than investments in a developed country due to greater market volatility, political and economic instability and governmental limitations etc.
- The Fund may also invest in derivatives and debt securities that are below investment grade or unrated which can involve material risks, e.g. counterparty default risk, insolvency or liquidity risk, and may expose the Fund to significant losses.
- The Fund's investments are primarily denominated in RMB. RMB is currently not a freely convertible currency and is subject to exchange controls and restrictions. Investors whose base currencies of investments are not in RMB should take into account the potential risk of loss arising from fluctuations in value between such currencies and the RMB.
- You should not make investment decision on the basis of this marketing material alone. Please read the prospectus for details and risk factors.
- The Fund is not authorized by the Securities and Futures Commission in Hong Kong and its shares are not available to the general public in Hong Kong.

# Investment objective

Value Partners Health Care Fund (the "Fund") aims to achieve longterm capital growth by investing primarily in equities and equity related securities in healthcare companies, such as pharmaceuticals, biotechnology, healthcare services, as well as medical technology and supplies, which derive a significant part of their revenue from the PRC and which are listed on stock markets on a worldwide basis, including mainland China.

# Performance update <sup>2</sup>

	Class A USD Unhedged	CSI 300 Index	Hang Seng China Enterprises Index
One month	+2.7%	+6.2%	-0.7%
Three months	+4.9%	+8.8%	+2.4%
Since launch	+9.1%	-14.9%	-10.8%

#### Top 5 securities holdings


Name	Industry <sup>3</sup>	%
China Resources Pharmaceutical Group Ltd	Pharmaceuticals, biotechnology & life sciences	7.6
Beijing Tong Ren Tang Chinese Medicine Co Ltd	Pharmaceuticals, biotechnology & life sciences	5.6
Livzon Pharmaceutical Group Inc	Pharmaceuticals, biotechnology & life sciences	5.2
Sinopharm Group Co Ltd	Pharmaceuticals, biotechnology & life sciences	4.0
Tianjin Zhongxin Pharmaceutical Group Corporation Limited	Pharmaceuticals, biotechnology & life sciences	3.9

These stocks constitute 26% of the fund.

#### Portfolio characteristics

20174	
20.7 times	
2.5 times	
1.5%	

## Geographical exposure by listing 5



#### **NAVs & codes**

Classes 7	NAV	ISIN	Bloomberg
Class A USD Unhedged	10.91	IE00BSM8VZ90	VPHCUAU ID
Class A HKD Unhedged	10.71	IE00BSM8VQ00	VPHCUAH ID
Class Z RMB (CNH) Unhedged	11.83	IE00BSM8VT31	VPHCUZR ID



#### **Fund facts**

Value Partners Hong Kong Limited Manager:

Base currency: USD

Launch date: Class A USD Unhedged/HKD Unhedged - 2 Apr 2015

Class Z RMB (CNH) Unhedged - 2 Apr 2015

Dealing frequency: Daily, Cutoff time 11:59am Irish time

Authorized by the Central Bank of Ireland as an Legal status:

undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011

HSBC Institutional Trust Services (Ireland) DAC Depositary: www.valuepartners-group.com and Financial Times Reporting:

#### Fee structure

	Class A	Class Z RMB (CNH)	
Minimum subscription:	USD10,000 or equivalent	RMB10,000,000	
Initial subscription fee:	Up to 5% of issue price		
Management fee:	1.5% p.a.	1.0% p.a.	
Performance fee 8:	15% of profit (high-on-high)		
Redemption fee:	Redeem within 6 months after purchase – 3% Redeem after 6 months – currently nil		

#### Senior investment staff

Chairman & Co-Chief Investment Officer: Cheah Cheng Hye Deputy Chairman & Co-Chief Investment Officer: Louis So

Deputy Chief Investment Officer: Renee Hung Senior Investment Director: Norman Ho, CFA

Investment Directors: Gordon  $\underline{Ip}$ , CFA; Kenny  $\underline{Tjan}$ , CFA; Michelle  $\underline{Yu}$ , CFA;

Senior Fund Managers: Kelly Chung, CFA; Doris Ho; Glenda Hsia;

Philip Li, CFA; Kai Mak

## Recent corporate awards



Asset Management Awards 2016 9 Fund House of the Year - Hong Kong - AsianInvestor



Thomson Reuters Lipper Fund Awards 2016 <sup>9</sup> **Best Equity Group (Hong Kong)** 

~ Thomson Reuters

All fund information is as of 30 Jun 2017 unless stated otherwise. Source: HSBC Institutional Trust Services (Ireland) DAC and Bloomberg.

All fund information is as of 30 Jun 2017 unless stated otherwise. Source: HSBC Institutional Trust Services (Ireland) DAC and Bloomberg.

1. Value Partners Health Care Fund is a sub-fund of Value Partners Ireland Fund plc (the "Company"). The Company is both authorized and supervised by the Central Bank of Ireland ("Central Bank") as an undertaking for Collective Investment in transferable Securities) Regulations (Indicated Indicated Indicat

For Swiss Qualified Investors: The sales prospectus, the Articles of Association, the Key Investor Information Document (KIID) as well as the annual and semi-annual reports of the Fund are available free of charge from the Representative in Switzerland.

Swiss Representative: FIRST INDEPENDENT FUND SERVICES LTD., Klausstrasse 33, CH-8008 Zurich. Swiss Paying Agent: NPB New Private Bank Ltd., Limmatquai 1, CH-8024 Zurich.

This report has not been reviewed by the Securities and Futures Commission of Hong Kong. Issuer: Value Partners Hong Kong Limited.